J&J’s Carvykti Demonstrates Extended Time to Symptom Worsening in Multiple Myeloma Patients
Johnson & Johnson (J&J; NYSE: JNJ) has released data from a Phase III study showing...
Cell-therapy
CARsgen Therapeutics Halts Clinical Studies for Three CAR-T Therapies in the US Following FDA Request
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that the US Food and Drug...
Chinese Biotech Precision Biotechnology Gets NMPA Green Light for Advanced Cancer Therapies
Chongqing Precision Biotechnology Co., Ltd, a Chinese biopharmaceutical company, has received approval from the National...
Taiwan Bio and TRACT Therapeutics Forge Partnership to Combat Organ Rejection
Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics,...
Stem-Cell Startup Xellsmart Earns FDA Orphan Drug Designation for ALS Therapy
Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug...
CARsgen Therapeutics Secures U.S. FDA Approval for CT071 Clinical Trials in Multiple Myeloma
CARsgen Therapeutics Holdings Ltd (HKG: 2171), based in China, has announced that it has received...
China’s State Council Unveils Comprehensive Plan to Boost Beijing’s Healthcare Sector
The State Council has unveiled a comprehensive “Work Plan” aimed at enhancing Beijing’s service industry...
JW Therapeutics Secures Priority Review for Carteyva in Relapsed/Refractory Mantle Cell Lymphoma
JW Therapeutics (HKG: 2126), based in China, has announced that its CAR-T cell therapy, Carteyva...
Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus
Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US...
AstraZeneca to Open R&D Center in Hong Kong, Focusing on Cell and Gene Therapies
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has concluded a roughly 12-month discussion period with...
SCG Cell Therapy’s SCG101 Receives Tacit Approval for Cholangiocarcinoma Clinical Trial in China
China’s Center for Drug Evaluation (CDE) website has indicated that SCG Cell Therapy Pte. Ltd’s...
BMS and 2seventy Bio’s Abecma Faces FDA Review Extension
The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...
Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies
Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership...
Biosmelt Pharma Partners with Shenzhen Eureka Biotechnology for Cell and Gene Therapy Advancements
Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with...
Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook
Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...
Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China
Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration...
Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China
Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a...
Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...
AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...